[Form 4] Maravai LifeSciences Holdings, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Form 4 snapshot: On 18 Jun 2025, Director Sean Laurence Cunningham filed a Form 4 disclosing an equity award from Maravai LifeSciences Holdings, Inc. (ticker MRVI).

Key transaction details: On 16 Jun 2025, Cunningham acquired 89,139 Class A common shares in the form of restricted stock units (RSUs) granted under the company’s 2020 Omnibus Incentive Plan at an indicated price of $2.16 per share. The RSUs vest in full on the earlier of one year from grant or the date of the 2026 annual meeting.

Post-grant ownership: The filing reports 138,055 shares held directly following the award. However, the footnote explains that these shares are held for the benefit of a GTCR-affiliated entity; Cunningham disclaims any pecuniary interest and is therefore not treated as the economic owner for Section 16 purposes.

Nature of the filing: No open-market purchase or sale occurred, and no derivative securities were involved. This is a routine board compensation grant rather than a signaling transaction. The filing does not contain earnings information, strategic announcements, or changes in control.

Insights

Securities Analyst

TL;DR: Routine RSU grant to director; neutral for valuation.

The 89,139-share RSU award increases reported direct holdings to 138,055 shares but is strictly a compensation event. Because the shares are unvested and ultimately attributable to GTCR, the grant does not reflect incremental open-market buying pressure. At a reference price of $2.16, the notional value is modest in the context of MRVI’s market capitalisation, so the award is unlikely to influence earnings per share, liquidity or near-term trading dynamics. Overall impact on shareholder value is neutral.

Corporate Governance Expert

TL;DR: Standard equity compensation aligns board but is not material.

Maravai continues to use service-based RSUs to align director incentives with shareholder interests. The one-year or 2026 AGM vesting schedule is typical and does not introduce unusual retention provisions. Because Cunningham holds the stock for a GTCR affiliate and disclaims economic ownership, any governance influence resides with GTCR rather than the individual. There are no red flags or policy deviations; the filing is administratively routine and carries a neutral governance impact.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CUNNINGHAM SEAN LAURENCE

(Last) (First) (Middle)

C/O GTCR, LLC

300 N. LASALLE SUITE 5600

(Street)

CHICAGO IL 60654

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
MARAVAI LIFESCIENCES HOLDINGS, INC. [ MRVI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/16/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	06/16/2025		A		89,139(1)	A	$2.16	138,055(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on June 16, 2025, which vest in full upon the earlier of one year from the date of grant or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders.

2. The Reporting Person holds these securities of the Issuer for the benefit of a GTCR-affiliated entity. Pursuant to the policies of the GTCR-affiliated entities, the Reporting Person must hold the securities on behalf of and for the benefit of the GTCR-affiliated entity. The Reporting Person disclaims any pecuniary interest in the securities, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of the securities for purposes of Section 16.

Remarks:

	/s/ Kurt Oreshack, by power of attorney for Sean Cunningham	06/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many shares did MRVI Director Sean Cunningham acquire on 16 Jun 2025?

89,139 Class A common shares were acquired in the form of RSUs.

What was the reported price for the RSUs granted to MRVI's director?

The filing lists an indicative price of $2.16 per share for the RSU grant.

When will the 89,139 RSUs awarded to Sean Cunningham vest?

They vest fully on the earlier of one year from grant or the 2026 annual meeting.

How many MRVI shares does Sean Cunningham report owning after the transaction?

The Form 4 shows 138,055 shares held directly following the award.

Does the Form 4 indicate any open-market buying or selling by the director?

No. The acquisition is a compensation-based RSU grant; no market transaction occurred.